Alpha-1 Antitrypsin Deficiency Market Report Scope & Overview:

The Alpha-1 Antitrypsin Deficiency Market was valued at USD 3.57 billion in 2025 and is expected to reach USD 9.64 billion by 2035, growing at a CAGR of 13.33% from 2026-2035. 

The alpha-1 antitrypsin deficiency market is experiencing growth because of increasing awareness about rare genetic diseases as well as an increasing number of advanced diagnostic technologies that facilitate the early and accurate identification of the disorder. Increasing genetic screening activities and increased newborn screening tests contribute towards diagnosis rates. An increasing incidence of respiratory and liver problems is fuelling the market growth. Regular innovations in augmentation therapy and biologic treatments are benefiting patients. Investments in biotech research and increasing clinical trials boost innovations. Moreover, positive reimbursement policies and better healthcare facilities in developed nations contribute to market growth.

The U.S. Food and Drug Administration (FDA) has approved weekly intravenous treatment with human alpha-1 antitrypsin (A1-PI) to raise blood levels in severe AATD patients with emphysema. AATD affects approximately 1 in 2,500 individuals globally, with higher prevalence in individuals of European descent. Many individuals with AATD, especially those with chronic obstructive pulmonary disease (COPD), remain undiagnosed, with studies suggesting up to 25% of COPD patients have never smoked yet are still affected by AATD.

Market Size and Forecast

• Market Size 2026E: USD 4.05Billion

• Market Size 2035: USD 9.64 Billion

• CAGR (2026-2035): 13.33%

• Fastest Growing Market: Asia Pacific

• Largest Market: North America

To Get more information on Alpha-1 Antitrypsin Deficiency Market - Request Free Sample Report

Alpha-1 Antitrypsin Deficiency Market Trends

• Rising prevalence of genetic and respiratory disorders is driving the alpha-1 antitrypsin deficiency (AATD) market.

• Growing adoption of augmentation therapy and enzyme replacement treatments is boosting market growth.

• Increasing awareness and early diagnosis initiatives are improving patient identification and treatment rates.

• Expansion of biopharmaceutical R&D and clinical trials is accelerating development of novel therapies.

• Focus on personalized medicine and genetic testing is shaping therapeutic strategies.

• Advancements in inhalation, gene therapy, and recombinant protein technologies are enhancing treatment options.

The U.S. Alpha-1 Antitrypsin Deficiency Market Size Outlook

The U.S. Alpha-1 Antitrypsin Deficiency Market was valued at USD 0.98 billion in 2025E and is expected to reach USD 2.61 billion by 2032, growing at a CAGR of 13.03% from 2026-2033. 

The alpha-1 antitrypsin deficiency market in the United States is witnessing growth owing to improved diagnostics, good awareness levels about rare diseases and their genetic factors, and prevalent genetic testing practices. There is efficient health care infrastructure for early diagnosis and management of the condition. Availability of pharmaceutical companies engaged in drug development and conducting clinical studies leads to the development of novel therapies. Positive reimbursement scenario and insurance support boost the availability of augmentation therapies.

Alpha-1 Antitrypsin Deficiency Market Segment Analysis

• By Therapy Type, intravenous therapy segment dominated the market in 2025 with ~56.79% share; inhalation therapy segment is the fastest growing (CAGR).

• By Patient Age Group, adult segment dominated the market in 2025 with ~74% share; pediatric segment is the fastest growing (CAGR).

• By Product Type, augmentation therapy segment dominated the market in 2025 with ~44% share; oxygen therapy segment is the fastest growing (CAGR).

• By Application, hospitals segment dominated the market in 2025 with ~52% share; specialty clinics segment is the fastest growing (CAGR).

By therapy type, intravenous therapy segment dominates the alpha-1 antitrypsin deficiency market, inhalation therapy segment is the fastest growing.

Intravenous therapy segment dominance in the alpha-1 antitrypsin deficiency market is fueled by the strong preference of the physicians towards direct injection into the bloodstream due to instant availability of adequate amounts of alpha-1 antitrypsin protein in severely deficient patients. This method is associated with higher safety of drug administration, increased control over dosage, and more efficient outcomes; hence, physicians tend to favor the use of IV drugs in such conditions. This combined with effective reimbursement practices contributes to the sustained leadership of the segment.

Inhalation therapy segment fastest growth in the alpha-1 antitrypsin deficiency market is driven by an increasing need for safer and more comfortable treatment methods suitable for prolonged therapy. Innovations in technology used for inhalers and nebulizers enable better efficacy in administering the drug as well as the possibility of carrying out treatment at home. The ease of use and growing effectiveness of this method for mild and moderate cases, as well as an improving home health care infrastructure, contributes to the segment's high growth rate.

By patient age group, adult segment dominates the alpha-1 antitrypsin deficiency market, pediatric segment is the fastest growing

Adult segment dominance in the alpha-1 antitrypsin deficiency market is owing to the higher incidence of disease diagnosis and the increased presence of pulmonary and hepatic problems among adults. The availability of well-established procedures and the provision of augmentation therapy play important roles in fostering acceptance of treatments among patients within this category. Active participation in the health care sector and regular monitoring make it easier to achieve sustained use of the treatment.

Pediatric segment fastest growth in the alpha-1 antitrypsin deficiency market is due to growing genetic testing initiatives and increased knowledge about inherited disorders. Early detection allows for quick medical response and lowers the risks associated with the deterioration of organs. Advancements in formulations and the improvement of supportive care mechanisms provide additional assistance in terms of treatment acceptance. Increased attention to preventive medicine and neonatal screening contribute to fast adoption in the Market.

By product type, augmentation therapy segment dominates the alpha-1 antitrypsin deficiency market, oxygen therapy segment is the fastest growing

Augmentation therapy segment dominance in the Alpha-1 Antitrypsin Deficiency Market due to its function as the primary modifiable treatment that involves the replacement of deficient alpha-1 antitrypsin proteins in the patient, strong recommendations from clinical guidelines, proven efficacy over time, and physicians' favorability in prescribing this modality for the treatment of severe cases. The availability of hospital resources as well as reimbursement policies ensures consistency in usage. These trends are expected to maintain the prominence of this segment in the Market.

Oxygen therapy segment fastest growth in the Alpha-1 Antitrypsin Deficiency Market is due to the increased incidences of hypoxemia and the demand for oxygen therapies. The increased availability of portable oxygen equipment will contribute significantly to the growth of this market segment. Growth in the oxygen therapy segment can be attributed to increased home healthcare facilities and convenience of usage in the Market.

By application, hospital segment dominates the alpha-1 antitrypsin deficiency market, specialty clinics segment is the fastest growing

Hospital segment dominance in the Alpha-1 Antitrypsin Deficiency Market is due to the presence of advanced diagnostic facilities, infusion services, and respiratory units that are necessary for treating severe cases. Hospitals offer a multidisciplinary approach to tracking treatment response and managing possible complications, resulting in increased safety and effectiveness of treatments. Efficient reimbursement procedures and well-established clinical guidelines further enhance treatment in hospitals. The presence of severe cases and new patients ensures dominance of hospitals in the Market worldwide.

Specialty clinics segment fastest growth in the Alpha-1 Antitrypsin Deficiency Market is due to an increasing trend towards outpatient treatment and patients' preference to undergo long-term disease management not in hospitals but in specialty clinics. Increased accessibility of respiratory physicians and treatment programs allows enhancing convenience of treatment process and its continuity. Decreased costs and shorter waiting periods are additional factors behind the growing popularity of specialty clinics in the Deficiency Market.

Regional Analysis

North America Alpha-1 Antitrypsin Deficiency Market Insights

The North American region had the largest share of 39% in the Alpha-1 Antitrypsin Deficiency Market in 2025, owing to its excellent healthcare system and high awareness regarding rare genetic disorders. The region is well-equipped with superior diagnostic techniques, large-scale genetic screening programs, and augmentation treatments that were adopted in the earlier stage of development. Key pharma companies operating in the region along with clinical studies aid market expansion. The favorable reimbursement structure and availability of insurance facilities facilitate patient accessibility to the treatment procedures. Respiratory diseases are prevalent in the region, while the emphasis on precision medicines bolsters its market dominance.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Alpha-1 Antitrypsin Deficiency Market Insights

The alpha-1 antitrypsin deficiency market has a very prominent presence in Europe owing to their advanced healthcare system and awareness about rare genetic diseases. The use of advanced diagnostics and newborn screening has facilitated early diagnosis. Presence of research institutes and pharmaceutical firms has led to continuous innovation in treatment. Positive payment policies in some countries have enhanced the access to augmentations among patients. Increased efforts toward precision medicine and clinical trials for pulmonary and hepatic diseases enhance the market growth prospects. Increased spending on healthcare coupled with a coordinated approach to rare diseases will boost market growth further.

Asia Pacific Alpha-1 Antitrypsin Deficiency Market Insights

The Asia Pacific market is forecasted to show high CAGR of 15.85% during 2026-2035, backed by increasing awareness about rare genetic diseases as well as improvement in healthcare infrastructure. Adoption of innovative diagnostic techniques, as well as increased availability of genetic tests, are aiding in early diagnosis of the condition. Other factors adding impetus to demand include government spending on healthcare infrastructure upgrades, as well as an increasing number of patients with respiratory diseases. Presence of a significant number of pharmaceutical companies in the region, along with ongoing clinical trials, is also adding strength to growth.

Middle East & Africa and Latin America Alpha-1 Antitrypsin Deficiency Market Insights

Middle East & Africa and Latin America are emerging markets for Alpha-1 Antitrypsin Deficiency, due to the presence of better healthcare facilities as well as the steady development of diagnostic capabilities. Despite the current lack of awareness regarding genetic respiratory diseases, there are ongoing efforts on the part of governments as well as the healthcare sector to improve it. There is still a certain lack of access to advanced treatments due to their expensive cost structure. Yet, the improvement in healthcare infrastructure in addition to increased specialization clinics are helping develop the market. Increased cooperation with foreign pharmaceutical firms will further boost drug availability.

Market Dynamics

Growth Drivers: Technological advancements in therapies and supportive healthcare infrastructure are accelerating the Alpha-1 Antitrypsin Deficiency Market expansion globally

Innovations in intravenous augmentation therapies, inhalation treatments, and biologics are enhancing efficacy and safety profiles for AATD patients. Advanced healthcare infrastructure, including specialty clinics and home care services, allows broader patient access to these therapies. Integration of telemedicine and monitoring devices improves adherence, follow-ups, and patient management. Pharmaceutical investments in R&D and strategic collaborations enable faster clinical trials and regulatory approvals. These advancements make treatment more accessible, reliable, and effective, directly boosting adoption rates. Improved healthcare facilities combined with new therapeutic innovations are key enablers of sustained market growth and long-term competitiveness.

Beam Therapeutics is advancing BEAM-302 base-editing gene therapy to correct the AATD mutation, restoring functional protein levels and preventing organ damage; Phase 1/2 positive data reported in March 2025.

Wave Life Sciences is developing RNA editing therapy that repairs faulty transcripts without altering DNA, enabling restoration of functional AAT protein; showed significant protein production in two patients after a single dose in October 2024.

Grifols is working on Alpha-1 15% subcutaneous formulation, a next-generation augmentation therapy designed to improve convenience and patient adherence through at-home administration; Phase 1/2 study reached second cohort enrollment in February 2025.

Arrowhead Pharmaceuticals is developing ARO-AAT RNAi therapy that suppresses misfolded AAT protein production to reduce liver toxicity and fibrosis; received FDA Breakthrough Therapy Designation and completed Phase 2 SEQUOIA enrollment.

Restraints: Low disease awareness and delayed diagnosis hinder rapid adoption and expansion of Alpha-1 Antitrypsin Deficiency Market globally

Many patients remain undiagnosed due to the rarity of the disorder and lack of routine genetic screening. Symptoms often mimic other respiratory conditions, leading to delayed identification and treatment. Limited patient and physician awareness reduces early intervention, slowing therapy adoption. Geographic disparities in healthcare infrastructure exacerbate these challenges, particularly in underdeveloped regions. These factors prevent optimal utilization of available therapies, reducing market potential. Awareness campaigns, early screening programs, and educational initiatives are critical to overcoming these obstacles, but until widespread knowledge and diagnostic improvements occur, market growth remains constrained by delayed treatment initiation and low patient engagement.

Opportunities: Growing focus on gene therapies and personalized medicine creates significant opportunities in Alpha-1 Antitrypsin Deficiency Market

Advancements in gene editing, RNA-based therapies, and personalized treatment approaches offer potential curative solutions for AATD, beyond symptomatic management. These innovative therapies can improve patient outcomes, reduce long-term healthcare costs, and address the underlying genetic cause. Pharmaceutical companies and biotech startups are investing heavily in R&D for next-generation treatments. Clinical trials and regulatory support are expanding, allowing accelerated adoption upon approval. The shift toward precision medicine creates opportunities for differentiated products, strategic partnerships, and novel therapeutic pipelines. These developments position the market for long-term growth and higher patient penetration globally.

Recent Developments:

• 2025: Sanofi and Alnylam continued advancing fitusiran (Qfitlia), an RNAi therapy impacting coagulation pathways, reflecting broader pipeline innovation in rare disease management, including conditions associated with alpha-1 antitrypsin deficiency-related complications.

• 2025: Takeda gained FDA approval for expanded GLASSIA vial sizes (1g, 4g, and 5g). The update streamlines infusion logistics for alpha-1 antitrypsin deficiency patients and reduces the number of vials required per dose, improving home infusion efficiency and treatment adherence.

• 2024: Sanofi reported Phase 2 success for efdoralprin alfa (SAR447537), showing improved functional alpha-1 antitrypsin levels compared with standard plasma-derived therapy. The study demonstrated potential for longer dosing intervals and improved patient convenience in AATD-related emphysema treatment.

• 2024: CSL Behring launched new 4-gram and 5-gram vial sizes for ZEMAIRA (AAT augmentation therapy). The initiative aimed to reduce vial burden per infusion and improve treatment convenience for patients with severe alpha-1 antitrypsin deficiency requiring weight-based dosing.

• 2023: Grifols introduced 4-gram and 5-gram vial sizes for PROLASTIN, a leading AAT augmentation therapy. The update reduced reconstitution complexity and improved dosing flexibility for clinicians treating severe alpha-1 antitrypsin deficiency, supporting long-term management of progressive emphysema.

• 2023: Grifols completed early clinical evaluation (Phase 1/2 Cohort 1) of its Alpha-1 Proteinase Inhibitor subcutaneous formulation (Alpha-1 15%). The study aimed to improve convenience over intravenous therapy, potentially enabling at-home administration and reducing treatment burden for patients with severe AATD-related lung disease.

Alpha-1 Antitrypsin Deficiency Market Key Players are:

• Grifols S.A.

• Takeda Pharmaceutical Company Limited

• CSL Behring

• Kamada Pharmaceuticals

• GlaxoSmithKline plc

• AstraZeneca Plc

• Boehringer Ingelheim International GmbH

• Pfizer Inc.

• Arrowhead Pharmaceuticals, Inc.

• Vertex Pharmaceuticals Incorporated

• Mereo Biopharma Group plc

• Dicerna Pharmaceuticals, Inc.

• Inhibrx, Inc.

• Teva Pharmaceutical Industries Ltd.

• LFB Biomedicaments S.A.

• Alnylam Pharmaceuticals, Inc.

• Sanofi S.A.

• CHIESI Farmaceutici S.p.A.

• Epicrispr Biotechnologies, Inc.

• Intellia Therapeutics, Inc.

Alpha-1 Antitrypsin Deficiency Market Report Scope: